Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate-to-severe atopic dermatitis: analysis of the randomized phase 3 studies SOLO 1 & SOLO 2, AD ADOL, and CHRONOS.

Like Comment
Pruritus (itch) is a cardinal symptom in atopic dermatitis (AD).Evaluate the timing and effect of dupilumab on itch.Analysis of data from 1,505 patients with moderate-to-severe AD included in four randomized controlled studies, treated for up to 52 weeks. Adults received dupilumab 300 mg every 2 weeks (q2w) or placebo monotherapy (SOLO1-2; NCT02277743, NCT02277769), with concomitant topical corticosteroids (CHRONOS, NCT02260986); adolescents (12-<18 years) were treated with dupilumab monotherapy q2w (200 mg baseline weight <60 kg, 300 mg 60 kg) or placebo (AD ADOL NCT03054428).Dupilumab showed significant rapid improvements from baseline in daily Peak Pruritus Numerical Rating Scale (PP-NRS) scores vs placebo, by day 2 in adults and day 5 in adolescents. At treatment end, dupilumab vs placebo/control had greater least-squares mean percent change from baseline in the weekly average of PP-NRS scores: SOLO -47.5% vs -20.5%; AD-ADOL -47.9% vs -19.0%; CHRONOS -57.3% vs -30.9% (P < .0001 for all).Short duration of monotherapy trials (16 weeks).Across four randomized trials, dupilumab treatment showed rapid and sustained improvements in the magnitude of itch, starting with first dose; responses progressively increased and were sustained through to the end of treatment, up to 1 year.

Click here to read the full article @ Journal of the American Academy of Dermatology
Go to the profile of ClinOwl


The wider, wiser view for healthcare professionals. ClinOwl signposts the latest clinical content from over 100 leading medical journals.
2311 Contributions
0 Following

No comments yet.